---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-068942"
form_type: "8-K"
ticker: "SXTP"
cik: "0001946563"
company_name: "60 DEGREES PHARMACEUTICALS, INC."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:27:36.194812+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# 60 Degrees Pharma grants UK right of reference to ARAKODA NDA for SJ733 Phase IIb trial

## Summary
- Granted University of Kentucky right of reference to ARAKODA NDA for FDA review of data supporting SJ733 Phase IIb study.
- Phase IIb will combine SJ733 (oral ATP4 inhibitor) with tafenoquine for radical cure of Plasmodium vivax malaria.
- Study funded by Global Health Innovative Technology Fund; Eisai managing trial material manufacturing and non-clinical studies.
- 60 Degrees Pharma will supply tafenoquine and placebos as study drugs for the trial.

## SEC filing metadata
- accession: 0001213900-24-068942
- form_type: 8-K
- ticker: SXTP
- cik: 0001946563
- company_name: 60 DEGREES PHARMACEUTICALS, INC.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1946563/000121390024068942/0001213900-24-068942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1946563/000121390024068942/ea0211411-8k_60degrees.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-068942
- JSON: https://secwatch.observer/filing/0001213900-24-068942.json
- Plain text: https://secwatch.observer/filing/0001213900-24-068942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.